Document:

Exhibit 10.7.3

 

Certain identified
information has been excluded from the exhibit pursuant to Item 601(a)(6) of Regulation S-K due to personal privacy concerns or pursuant
to Item 601(b)(10)(iv) because it is both not material and is the type of information that the registrant treats as private or confidential.
Redacted information is indicated by: [***]

 

This third amendment to the UNIVERSITY HEALTH NETWORK
- AMORFIX LIFE SCIENCES LICENSE AGREEMENT (the “Third Amendment”) is made effective this 4th day of November,
2013, (the “Effective Date”) by and between:

 

UNIVERSITY HEALTH NETWORK, an Ontario corporation
incorporated by special statute under the Toronto Hospital Act, 1997, having a business office at 101 College Street, Suite 150,
Heritage Building, MaRS Centre, Toronto, Ontario M5G 1L7 Canada (“UHN”);

 

And

 

AMORFIX LIFE SCIENCES LTD., a Canada corporation
with offices located at 3403 American Drive, Mississauga, ON L4V 1T4, (“AMF”);

 

WHEREAS

 

		A.	The Parties entered into an exclusive license agreement effective the 4th day of April, 2006 (the “Agreement”),
which was amended on the 13th day of July, 2006 (the “First Amendment”), was further amended on the 11th day of July 2007
(the “Second Amendment”) and was further amended pursuant to a letter agreement as between UHN, AMF and Biogen in order
to accommodate a sublicense as between AMF and Biogen (the “Letter Agreement”) all collectively the “License
Agreements”.

 

		B.	The Agreement dictates that UHN grants to AMF an exclusive license in any and all of its rights to the Technology, and Technology
is defined in the Agreement both as (i) “a SOD1 [human superoxide dismutase 1] exposed dimer interface antibody” and
later as (ii) “all allowed claims in Intellectual Property in and to the invention described in and/or listed in Schedule “A”
and all Intellectual Property Rights related to or arising therefrom, excluding Improvements by UHN and Improvements by Licensee”.
Pursuant to the Agreement, “Improvements by UHN” is a defined term, but “Improvements by Licensee” is not. None
of the License Agreements provide a definition of Improvements by Licensee.

 

		C.	The Second Amendment recognized that UHN possessed further ownership rights in the “Technology” that should have been
identified in the original Agreement, and replaced Schedule “A” with Amended Schedule “A’ which lists various
intellectual property including the following:

 

		a.	priority patent applications [***]; [***], and [***] and [***] [sic [***]] and the PCT counterpart,

 

		b.	all applications that may be filed based on the foregoing, including, without limitation, all regular, divisional or continuation,
applications based in whole or in part on the foregoing, and all applications corresponding to the foregoing filed in any country

 

		c.	all issued and unexpired patents resulting from any of the applications described above.

 

		d.	all issued and unexpired reissues, reexaminations, renewals or extensions that may be based on any of the patents described above
(the “Amended Schedule “A” Intellectual Property”)

 

     

     

    

 

		D.	Pursuant to the License Agreements, “UHN shall partially own all applications and registrations for Intellectual Property Rights
for the Technology”;

 

		E.	AMF has had the primary responsibility for prosecuting all intellectual property relating to human superoxide dismutase 1 (“SOD
1”). AMF has dropped UHN ownership in US application no. [***] (now issued as [***]) and US application no. [***] (now issued
as [***]) which is a continuation in part application of [***]. Both [***] and [***] are considered Amended Schedule “A” Intellectual
Property.

 

		F.	AMF is now requesting that UHN assign ownership in US Application No. [***] filed on June 8, 2011 entitled Methods
and Compositions to Treat and Detect Misfolded-SOD1 Mediated Diseases, which is a continuation application of [***] and US Application
No. [***], filed on December 24, 2010 entitled Methods and Compositions to Treat and Detect Misfolded-SOD1 Mediated Diseases,
(the “Applications”) in order to overcome and obviousness double patenting rejections with Amended Schedule A Intellectual
Property now solely owned by AMF;

 

		G.	The Parties agree that ownership of the Amended Schedule “A” Intellectual Property by UHN is not of primary concern. Instead,
the Parties wish to ensure that UHN’s contribution the patented technology relating to disease specific epitopes of human superoxide
dismutase I, via its inventors Avi Chakrabartty and Rishi Rakhit, is appropriately rewarded.

 

NOW THEREFORE this Amendment witnesses that in consideration of the
premises and mutual agreements and covenants herein contained, the receipt and sufficiency of which is hereby mutually acknowledged, the
Parties covenant and agree as follows:

 

1.            Amended
and Restated License Agreement

 

1.1            The
Parties shall amend and restate the License Agreements (the “Amended and Restated License Agreement”) to ensure that
the Amended and Restated License Agreement is consistent with the License Agreements as further clarified by this Third Amendment. To
the extent that there is a question of the intention of the Parties when drafting the Amended and Restated License Agreement, the intention
of the Parties as determined with reference to this Third Amendment shall govern.

 

1.2            The
Amended and Restated License Agreement shall amend Section 3.1 (dealing with the consideration of the License granted), such that
the Licensee agrees to make payments to UHN according to new Schedule “C” attached hereto as Appendix “A” (“New
Schedule “C””).

 

1.3            The
Amended and Restated License Agreement shall define the Technology to be “the invention(s) described in and/or listed in Amended
Schedule “A” and all Intellectual Property Rights therein”, regardless of ownership, on the basis that the Parties recognize
that of primary relevance to the intention of the Parties is the consideration as outlined in New Schedule “C”.

 

1.4            The
Amended and Restated License Agreement shall clarify that the Buyout Option applies when UHN assigns all interests pursuant to New Schedule
 “C” and any residual ownership interests in the Technology (as newly defined in Section 1.3).

 

1.5            The
Amended and Restated License Agreement shall clarify that the Licensee will not challenge the validity of any Intellectual Property Rights
in the Technology (as newly defined in Section 1.3).

 

    2 

     

    

 

2.            Amended
and Restated License Agreement. UHN shall assign to AMF its ownership rights in the Applications in the assignment document attached
hereto as Appendix “B” (the “Assignment”) and shall further assign all other ownership rights in and to
any Intellectual Property Rights in the Technology (as newly defined in Section 1.3) required to give effect to the intention of
the Parties as outlined in this Third Amendment.

 

3.            Counterparts.
This Third Amendment may be executed in as many counterparts as may be necessary or by facsimile and each such counterpart or facsimile
so executed shall be deemed to be an original and such counterparts and facsimile copies together shall constitute one and the same instrument.

 

In witness whereof the Parties hereto have executed this Amendment
effective the date first written above,

 

	UNIVERSITY HEALTH NETWORK	AMORFIX LIFE SCIENCES LTD.
	 	 
	
    /s/ Christopher J. Paige
	/s/ Warren Whitehead
	Per: Christopher J. Paige, PhD	Per: Warren Whitehead
	Title: Vice President Research	Title: Chief Financial Officer
	I have the authority to bind the entity.	I have the authority to bind the entity.

 

    3 

     

    

 

APPENDIX “A”

 

New Schedule “C”

 

Milestone Payments

 

	Diagnostic	Payment
	Upfront fee upon the signing of the Agreement.	$[***]
	The first detection of any Disease Specific Epitope (DSE) in a human CSF sample where such detection would infringe a Valid Claim of the Technology (where a Valid Claim as defined in this Appendix A is an allowed claim or a claim that later becomes allowed, irrespective of whether such claim is subsequently abandoned, disclaimed or dedicated to the public) where Avi Chakrabartty and/or Rishi Rakhit (whether alone or in conjunction with non-UHN inventors) are Inventors of some or all of the subject matter encompassed within the Valid Claim (as inventorship is defined pursuant to U.S. Patent Law)	$[***]
	The first detection of any DSE epitope in a human blood sample, where such detection would infringe a Valid Claim of the Technology where Avi Chakrabartty and/or Rishi Rakhit (whether alone or in conjunction with non-UHN inventors) are inventors of the subject matter encompassed in the Valid Claim, are Inventors of some or all of the subject matter encompassed within the Valid Claim.	$[***]
	First Product approval in Canada, USA, Europe or Japan where the Product would infringe a Valid Claim of the Technology where Avi Chakrabartty and/or Rishi Rakhit (whether alone or in conjunction with non-UHN inventors) are Inventors of some or all of the subject matter encompassed within the Valid Claim.	$[***]
	Therapeutic	 
	Upfront fee upon the signing of the Second Amendment.	$[***]
	Completion of Phase I studies where the activities pursuant to the Phase I studies, or the use of the product for which Phase I studies are being done, would infringe a Valid Claim of the Technology, where Avi Chakrabartty and/or Rishi Rakhit (whether alone or in conjunction with non-UHN inventors) are Inventors of some or all of the subject matter encompassed within the Valid Claim.	$[***]
	Completion of Phase II studies where the activities pursuant to the Phase II studies, or the use of the product for which Phase II studies are being done, would infringe a Valid Claim of the Technology, where Avi Chakrabartty and/or Rishi Rakhit (whether alone or in conjunction with non-UHN inventors) are Inventors of some or all of the subject matter encompassed within the Valid Claim.	$[***]
	Completion of Phase III studies where the activities pursuant to the Phase III studies, or the use of the product for which Phase III studies are being done, would infringe a Valid Claim of the Technology, where Avi Chakrabartty and/or Rishi Rakhit (whether alone or in conjunction with non-UHN inventors) are Inventors of some or all of the subject matter encompassed within the Valid Claim.	$[***]
	First Product approval in Canada, USA, Europe or Japan where the Product and/or the use thereof would infringe a Valid Claim of the Technology, where Avi Chakrabartty and/or Rishi Rakhit (whether alone or in conjunction with non-UHN inventors) are Inventors of some or all of the subject matter encompassed within the Valid Claim.	$[***]

 

    4 

     

    

 

Buyout Payments under section 2.2

 

	Diagnostic	Payment
	Upon signing of this Agreement	$[***]
	a. Detection of any DSE Epitope, in CSF human samples where such detection would infringe a Valid Claim of the Technology, where Avi Chakrabartty and/or Rishi Rakhit (whether alone or in conjunction with non-UHN inventors) are Inventors of some or all of the subject matter encompassed within the Valid Claim.	$[***]
	b. Detection of any DSE Epitope in blood samples where such detection would infringe a Valid Claim of the Technology, where Avi Chakrabartty and/or Rishi Rakhit (whether alone or in conjunction with non-UHN inventors) are Inventors of some or all of the subject matter encompassed within the Valid Claim	$[***]
	Therapeutic	 
	Upon signing of this Agreement	$[***]
	a. Completion of Phase I studies where the activities pursuant to the Phase I studies, or the use of the product for which Phase I studies are being done, would infringe a Valid Claim of the Technology, where Avi Chakrabartty and/or Rishi Rakhit (whether alone or in conjunction with non-UHN inventors) are Inventors of some or all of the subject matter encompassed within the Valid Claim.	$[***]
	b. Completion of Phase II studies where the activities pursuant to the Phase II studies, or the use of the product for which Phase II studies are being done, would infringe a Valid Claim of the Technology, where Avi Chakrabartty and/or Rishi Rakhit (whether alone or in conjunction with non-UHN inventors) are Inventors of some or all of the subject matter encompassed within the Valid Claim.	$[***]

 

    5 

     

    

 

Royalty

 

	Field	
    Percent Royalty rate from Net Sales received by the Licensee or sublicensees
    in each Quarter Yearly Period for all Products and Services sold, where such Product or Service infringes a Valid Claim of the Technology,
    where Avi Chakrabartty and/or Rishi Rakhit (whether alone or in conjunction with non-UHN inventors) are inventors are Inventors of some
    or all of the subject matter encompassed within the Valid Claim.

    Each payment shall be made within thirty (30) days of the end of each
    Quarter Yearly Period; and,

	Diagnostic Use	[***]%
	Therapeutic Use	[***]%

 

    6 

     

    

 

APPENDIX B:

ASSIGNMENT

 

ASSIGNMENT

 

WHEREAS, Amorfix Life Sciences Ltd. whose
full post office address is 3403 American Drive, Mississauga, Ontario L4V 1T4, Canada, and University Health Network whose full
post office address is R. Fraser Elliott Building, 1st Floor 190 Elizabeth St., Toronto, ON M5G 2C4, Canada are the owners of the
inventions disclosed in U.S. Patent Application No. 12/978,478, filed on December 24, 2010 entitled Methods
and Compositions to Treat and Detect Misfolded-SOD1 Mediated Diseases, and in U.S. Patent Application No. 13/155,939,
filed on June 8, 2011 entitled Methods and Compositions to Treat and Detect Misfolded-SOD1 Mediated Diseases (hereinafter
 “the Applications”);

 

WHEREAS, Amorfix Life Sciences Ltd. desires
to acquire all the rights in and to the Applications.

 

NOW THEREFORE, in consideration of the execution
of the Third Amendment to which this Assignment is attached as Appendix “B”, and other good and valuable consideration,
the receipt and sufficiency of all of which is hereby acknowledged, University Health Network agrees to and does hereby sell, transfer
and set over to Amorfix Life Sciences Ltd., all their right, title and interest in and to the Applications in the United
States of America, and all Patents and continuing applications deriving therefrom, including any divisionals, continuations, re-examinations,
reissues and extensions thereof in the United States of America, to be held and enjoyed by Amorfix Life Sciences Ltd. its assigns
and successors.

 

Amorfix
Life Sciences Ltd. and University Health Network authorize and empower Bereskin & Parr LLP/S.E.N.C.R.L., s.r.l.,
whose complete address is Scotia Plaza, 40 King Street West, 40th Floor, Toronto, Ontario M5H 3Y2, to insert on this Assignment any further
identification which may be necessary or desirable in order to comply with the rules for recordation of this document in the United
States and to correct any clerical error in this assignment.

 

    7 

     

    

 

The Commissioner of Patents & Trademarks
is hereby authorized and requested to issue any Letters Patent for the Applications, and all related applications thereon, to the
Assignee, to the full end of the term for which Letters Patent may be granted, as fully and entirely as the same would have been held
by the Assignors had this Assignment not been made.

 

The Parties confirm their express wish that this
Assignment be drawn up in the English language. Les parties conferment leur volonte expresse que cette cession soft recligee en langue
anglaise.

 

SIGNED AT Toronto, ON, this 6th
day of November, 2013.

 

	/s/ Jacquel S	 	/s/ Christopher Paige
	Witness	 	University Health Network

 

SIGNED AT Toronto, ON, this 4th
day of November, 2013.

 

	/s/
    Lynda Covello 	 	/s/
    Warren Whitehead
	Witness	 	Amorflix Life Sciences Ltd.

 

    8Exhibit 10.8

 

Certain identified information has been excluded from the exhibit pursuant to Item 601(a)(6) of Regulation
S-K due to personal privacy concerns. Redacted information is indicated by: [***]

 

CONSULTING AGREEMENT

 

THIS AGREEMENT made as of and effective from

 

April 1, 2021, BETWEEN:

 

ELLIOT PAUL GOLDSTEIN, MD.

 

[***]

 

(hereinafter called the “Consultant”)

 

AND:

 

ProMIS Neurosciences, Inc., a corporation existing under the laws
of the Province of Ontario

 

1920 Yonge St., Suite 200

 

Toronto, Ontario, M4S 3E2

 

(hereinafter called “ProMIS” or the “Sponsor”)

 

WHEREAS Dr. Goldstein is to be retained for CEO consulting services,

 

AND WHEREAS ProMIS wishes to retain the services of Dr. Gioldstein
to provide certain services as consulting CEO;

 

THIS AGREEMENT WITNESSETH that in consideration of the mutual covenants
herein contained and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties hereto
agree as follows:

 

1.0            Consulting
Services: ProMIS hereby retains the Consultant and the Consultant agrees to be available to perform
services as described in Appendix A.

 

2.0            Term:
Subject to termination in accordance with Section 13.0, ProMIS hereby retains the Consultant for a term of 6 months commencing April 1,
2021. This Agreement may be renewed upon mutual agreement on substantially the same terms herein.

 

3.0            Compensation:
In exchange for the advice and services to be provided by the Consultant as set out in Section 1.0 and Appendix A, ProMIS agrees
to pay and the Consultant hereby acknowledges that the following compensation represents payment in full for such services and advice:

 

		(a)	ProMIS shall pay Consultant for his services at the rate of US $5000.00 per month (five thousand US dollars).
During the contract term, it is understood that the Consultant shall be available for the requirements of ProMIS to achieve the objectives
set out in Appendix A. During the contract term, it is also understood that the Consultant
will devote, on average 2 days per week up to a maximum of 8 days per month of his time to achieve the Objectives set forth in Appendix
A.

 

     

     

    

 

4.0            Expenses.
If the Consultant incurs out-of-pocket expenses in the course of providing the services hereunder, ProMIS shall reimburse the Consultant
for such expenses, provided that the Consultant has obtained approval in writing from ProMIS prior to incurring any such expense of $500
or greater. The Consultant shall provide receipts for expenses to ProMIS with any request for reimbursement.

 

5.0            Terms
of Payment. Payment is due and payable not more than 15 calendar days after receipt of an invoice
by ProMIS from the Consultant. ProMIS shall send payment to the Consultant at the address set out on the first page hereof or such
other address as the Consultant may advise ProMIS in writing from time to time, or; preferably send such payment via wire transfer
to the Consultant’s personal bank account.

 

6.0            Hours.
Notwithstanding anything contained in this Agreement, the parties acknowledge and agree that the Consultant shall spend no more than eight
days per month on the performance of the services hereunder; provided, however, that the Consultant may, in his sole discretion, consent
in writing to a greater number of hours per month in unique or special circumstances.

 

7.0            Non-Competition.
Consultant may, at any time during the term of this Agreement and thereafter, provide services to other corporations or business entities
provided that such services do not directly compete with those business activities of ProMIS .

 

8.0            Non-Disclosure.

 

8.1            The
Consultant agrees that any information provided by ProMIS to the Consultant or which the Consultant learns about the business of ProMIS
as a result of providing services hereunder (“Confidential Information”) shall be considered confidential and the Consultant
agrees that he will not divulge or use for his own purposes or benefit such information without the prior written consent of ProMIS or
as may be required to properly provide the services of the Consultant herein. It is hereby expressly acknowledged that the Consultant
may be bound by confidentiality agreements other than with ProMIS and the Consultant hereby covenants and agrees to abide by the provisions
of such other agreements and to indemnify and hold ProMIS harmless with respect to the breach of any other confidentiality or non-disclosure
agreement.

 

8.2            The
restrictions set out in subsection 8.1 shall not apply to:

 

		(a)	any information which is, at the commencement of the term of this Agreement or at some later date, publicly
known under circumstances involving no breach of this Agreement;

 

		(b)	disclosure of Confidential Information where such disclosure is required by law, court order, court proceedings
or the rules of policies of any stock exchange or government or regulatory
authority having jurisdiction in the matter;

 

		(c)	disclosure of Confidential Information where such disclosure is consented to in writing by the Sponsor;

 

    2 

     

    

 

		(d)	any knowledge of Confidential Information that the Consultant independently obtained, other than through
a breach of this Agreement, either before or after the date of this Agreement; or

 

		(e)	disclosure of Confidential Information in accordance with the provisions of Section 9.0 hereof.

 

9.0            Intellectual
Property. Both parties agree that intellectual property including all inventions and discoveries
arising from the consulting services and activities of the Consultant shall be the property of ProMIS Neurosciences.

 

10.0            Independent
Contractor. In the performance of the services hereunder, the Consultant shall be an independent
contractor and shall not be an employee of the Sponsor. As such, the Consultant shall have full and complete discretion in determining
the manner, times and places for the performance of the services hereunder. Without limitation, the Sponsor acknowledges and agrees that
the Consultant shall also have or may have other outside consulting and business interests and that the Consultant is not obligated to
provide services to the Sponsor on an exclusive basis. Nothing contained herein shall be construed as creating a joint venture or partnership
between the Consultant and the Sponsor.

 

11.0            Governing
Laws. The provisions hereof shall be construed in accordance with the laws of the Province of
Ontario and the laws of Canada applicable therein.

 

12.0            Termination.

 

13.0            Either
party may terminate this Agreement upon 30 calendar days prior written notice to the other.

 

13.1            If
either party commits any breach or default of any terms or conditions of this Agreement and also fails to remedy such breach or default
within 15 calendar days after receipt of a written notice from the other party, the party giving notice may terminate this Agreement by
sending a notice of termination in writing to the party in breach. This termination will be effective as of the date of the receipt of
such notice. Such termination will be in addition to all other remedies available at law or in equity.

 

13.2            In
the event of any termination of this Agreement, the Sponsor shall pay the Consultant within 15 calendar days of receipt of an invoice
therefor, all consulting fees, reimbursable expenses and other amounts owing to the Consultant pursuant to the terms of this Agreement
to the date of termination.

 

    3 

     

    

 

14.0            Communications.
Any notice or other communication to be given in connection with this Agreement shall be given
in writing and may be given by personal delivery, electronic transmission or by registered or certified mail addressed to the recipient
as follows:

 

	To : Eugene Williams	
    ProMIS Executive Chairman

    ProMIS Neurosciences Inc,

    1920 Yonge St., Suite 200

    Toronto, Ontario, M4S 3E2

    Email: [***]

	 	 
	To the Consultant:	
    Eliot Goldstein, MD

    [***]

    Email: [***]

 

or such other address or individual as may be
designated by notice by any party to the other. Any such notice
or other communication shall be deemed to have been given
on the day delivered if delivered by personal delivery, on the day of transmittal thereof if given
by electronic transmission, and on the
fifth business day following the date of posting
if mailed.

 

15.0            Assignment.
This Agreement is not assignable by
either party without the prior written consent of the other party,
which shall not be unduly withheld.

 

16.0            Enurement.
This Agreement shall enure to the benefit of and be binding
upon the parties to this Agreement and their respective heirs,
executors, administrators, successors and permitted assigns.

 

17.0            Counterparts.
This Agreement may be executed in
one or more counterparts, each of which when executed shall be deemed
to be an original, but all of which taken together shall constitute
one and the same agreement. Counterparts may
be executed either in original or faxed form, or other form of
electronic transmission and the parties adopt any signatures received
by a receiving fax machine or by e-mail as original signatures
of the parties.

 

IN WI TNESS WHEREOF the
parties hereto have executed this Agreement as of the day
and year first above written.

 

On
behalf of ProMIS Neurosciences

 

	Per	 /s/ Eugene Williams	 
	Name/title: Eugene Williams, Executive Chairman	 
	 	 
	On behalf of the Consultant	 
	 	 
	Per	 /s/ Elliot Goldstein	 
	Name/title: Elliot Goldstein, MD	 

 

    4 

     

    

 

Appendix A

 

Title & objectives

 

Consultant CEO will report directly to the Executive Chairman. Objectives
will be set in agreement with the Executive Chairman.

 

    5

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00345-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00345-of-00352.parquet"}]]